| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology (F.B., I.M., G.P., F.A., S.M.) and Nuclear Medicine (M.P.), Department of Medical Sciences "M. Aresu," and Department of Cytomorphology, San Giovanni di Dio Hospital (M.L.L.), University of Cagliari, I-09042 Monserrato, Cagliari, Italy
Address all correspondence and requests for reprints to: Stefano Mariotti, M.D., Endocrinology, Department of Medical Sciences, Presidio di Monserrato, University of Cagliari, Strada Statale 554-bivio Sestu, I-09042 Monserrato, Cagliari, Italy. E-mail: mariotti{at}pacs.unica.it.
| Abstract |
|---|
|
|
|---|
Subjects and Methods: A total of 36 ultrasound-guided FNABs were performed in neck masses from 23 patients with borderline or high basal and pentagastrin-stimulated serum CT. Cytology and CT-FNAB were performed on a total of 18 TNs and three neck lymph nodes (LNs) from 12 patients examined before thyroidectomy, and on six suspicious local recurrences (LRs) and nine LNs from nine totally thyroidectomized MTC patients. On the basis of CT-FNAB values found in 15 non-MTC lesions, CT-FNAB more than 36 pg/ml was considered as indicative of MTC.
Results: All 21 positive CT-FNAB lesions (10 TNs, six LNs, and five LRs), 13 with positive cytology, were confirmed as MTC at histology. Of the 15 negative CT-FNAB suspicious masses (eight TNs, six LNs, and one LR), five displayed a benign lesion at histology. The remaining 10 cases, all with benign cytology, were not operated on, and no evidence of MTC was detected at follow-up. CT-FNAB reached 100% sensitivity and specificity for MTC, while cytology displayed 61.9% sensitivity and 80% specificity.
Conclusions: Ultrasound-guided CT-FNAB was the best tool to identify primary MTC and LRs/node metastases in MTC operated subjects. This may have important implications in the management of MTC.
| Introduction |
|---|
|
|
|---|
The aim of this study was to assess the clinical usefulness of CT-FNAB in the identification of primary MTC and its neck LN metastases or recurrences.
| Patients and Methods |
|---|
|
|
|---|
From 20032006, 36 US-guided FNABs were performed in 23 patients with high-serum CT. These included 21 lesions (18 TNs and three neck LNs) from 14 patients before thyroidectomy and 15 neck masses (six suspicious local recurrences and nine neck LNs) from nine patients after total thyroidectomy for MTC.
All patients (13 women, age range 3676 yr, and 10 men, age range 2569 yr) were submitted to an accurate physical examination, neck US, US-guided FNAB of neck mass for conventional cytology, and CT-FNAB. Basal serum and PG-stimulated CT were performed as detailed later. Thyroid 99mTc-pertechnetate scintiscan was also performed in most patients with TNs before surgery.
Conventional neck US and CFDS study
US and CFDS of the neck were performed using Sonoline G60S equipment (Siemens, Medical Solutions, Issaquah, WA) with a 813-mHz linear electronic transducer. All TNs and cervical masses were identified and localized, and their diameters were measured. Suspicious TNs and neck masses were identified according to standard criteria (6, 11) and submitted to FNAB under US visual control.
Hormonal assays
Serum CT and CT-FNAB measurements were performed using an ultrasensitive chemiluminescent assay (Immulite 2000 Calcitonin; Diagnostic Products Corp., Los Angeles, CA, distributed by Medical Systems Corp., Genoa, Italy). Normal range values for serum CT were less than 118 pg/ml for males and less than 112 pg/ml for females. Unless very elevated (>500 pg/ml), serum CT was assayed before and after stimulation with PG. For this purpose CT was assayed before, and two and 5 min after iv bolus of 0.5 µg/kg PG (Pentagastrin Injection BP; Cambridge Laboratories, Tyne and Wear, UK). Serum CT after PG stimulation was considered abnormal if more than 100 pg/ml (12).
Cytology and CT-FNAB
Written informed consent for the study was obtained before FNAB. US-guided FNAB was performed as previously reported (11, 13). Cytological examination was made by an experienced thyroid pathologist (M.L.L.), who was unaware of CT-FNAB results. Cytological diagnosis in TNs and LNs was expressed according to standard criteria, as previously detailed (11, 13). A specific diagnosis of MTC was attempted in all case when cytological features suggestive for this tumor were found (14). For the purpose of this study, cytology was considered "positive" when suggestive of malignant neoplasm with or without specific MTC characteristics and "negative" in the presence of benign pattern or inadequate sample.
After smear preparation, the needle was washed out with 500 µl CT-free serum dilution buffer and the solution processed for CT-FNAB measurement.
Histological diagnosis on surgical specimens was made using standard pathological techniques, including search of CT expression by immunohistochemistry.
Cutoff values for CT-FNAB
To interpret correctly the results of CT-FNAB, we had to establish a cutoff above which the CT-FNAB concentration in wash-out fluid could be considered expression of local CT production, rather than the result of peripheral blood contamination. For this purpose we retrospectively examined all CT-FNABs obtained from benign TNs and from non-MTC cervical masses of patients with borderline to markedly increased serum CT levels. On the basis of this analysis, all CT-FNABs more than 36 pg/ml (i.e. three times the maximal CT-FNAB concentration found in this group) were considered positive and diagnostic for MTC.
Statistical analysis
The sensitivity and specificity for primary MTC and MTC recurrences/LNs metastases were calculated by the Galen and Gambino formula (15).
| Results |
|---|
|
|
|---|
|
Together, high CT-FNAB concentrations (189 to >2000 pg/ml) were found in all histologically confirmed MTCs. In contrast, CT-FNAB in benign lesions was often undetectable (<1 pg/ml), and, in any case, not more than 12 pg/ml. When detectable, no difference was found between CT-FNAB from benign TNs and nonneoplastic neck masses (Fig. 1A
). To evaluate whether and to what extent the increased serum CT concentration could contribute to CT-FNAB, serum CT was compared with CT-FNAB of benign lesions (Fig. 1B
). A significant correlation between serum CT and CT-FNAB was found (r = 0.642; P < 0.009); the 95% confidence interval of the regression line slope was 0.0080.049, indicating that the contribution of serum CT in CT-FNAB should correspond to about 0.85% of serum CT.
The comparison of CT-FNAB with cytology and histology is shown in Table 1
. CT-FNAB was able to detect all 21 histologically proven primary or recurrent/metastatic MTCs, while cytology correctly identified only 13 cases (61.9%). On the other hand, none of the 15 lesions with negative CT-FNAB was MTC, as assessed by histology in five operated cases, and by clinical and US follow-up in the remaining 10 lesions (four TNs and six LNs). The diagnostic accuracy for MTC of cytology and CT-FNAB was calculated in the 26 operated lesions. CT-FNAB reached 100% sensitivity and specificity, while cytology displayed only 61.9% sensitivity and 80% specificity. False-negative cytological results (8 of 21, 38.1%) were mostly due to inadequate or insufficient material (7 of 8, 87.5%), while only in one case the diagnosis was "indeterminate follicular lesion."
|
| Discussion |
|---|
|
|
|---|
The above excellent diagnostic performance of CT-FNAB was obtained with a rather arbitrary cutoff of 36 pg/ml corresponding to three times the highest CT-FNAB concentration observed in our series of benign cervical lesions. However, we are aware that a fixed cutoff could not be always appropriate, particularly in patients with extremely high-serum CT, due to peripheral blood contamination of needle wash-out fluid. To characterize better this potential interference, we analyzed CT-FNAB concentrations found in benign neck masses from patients with increased serum CT. The results obtained, although limited by the small number of cases, strongly suggest that serum CT contribution to CT-FNAB does not exceed 5%, a value that could not account for any of the positive CT-FNABs found in this study. CT-FNABs in neck LN metastases or recurrences were not much higher than the corresponding serum CT, a finding in contrast with what was generally observed with Tg-FNAB (9, 10, 11). This may be due to differences in the respective amounts of Tg and CT within the metastatic cells or released into the interstitial fluid during needle aspiration.
In conclusion, our study provides the first demonstration that CT-FNAB is a highly reliable diagnostic procedure to identify primary and recurrent/metastatic MTC. The actual relevance of this technique in the management of MTC needs further longitudinal studies in a larger number of patients.
| Footnotes |
|---|
Disclosure Statement: The authors have nothing to disclose.
First Published Online April 3, 2007
Abbreviations: CFDS, Color flow Doppler sonography; CT, calcitonin; CT-FNAB, calcitonin assay in FNAB; FNAB, fine-needle aspiration biopsy; LN, lymph node; MTC, medullary thyroid carcinoma; PG, pentagastrin; Tg, thyroglobulin; TN, thyroid nodule; US, ultrasound.
Received February 12, 2007.
Accepted March 27, 2007.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C Scheuba, K Kaserer, A Moritz, R Drosten, H Vierhapper, C Bieglmayer, O A Haas, and B Niederle Sporadic hypercalcitoninemia: clinical and therapeutic consequences Endocr. Relat. Cancer, March 1, 2009; 16(1): 243 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Sippel, M. Kunnimalaiyaan, and H. Chen Current Management of Medullary Thyroid Cancer Oncologist, May 1, 2008; 13(5): 539 - 547. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |